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ABSTRACT
The human vitamin D-binding protein (hDBP) gene
is a member of a cluster that includes albumin,
a-fetoprotein and a-albumin genes. The common ori-
gin, physical linkage and hepatic expression of these
four genes predict shared regulatory element(s).
However, separation of hDBP from the other three
genesby1.5MbarguesthathDBPmaybeunderauto-
nomous control. To test for hDBP autonomy, mouse
lines were generated with a transgene containing the
hDBP gene along with extensive flanking sequences.
Expression of this transgenewas hepatic, robust and
proportional to transgene copy number. DNase I
hypersensitive site (HS) mapping revealed five
liver-specific HS at the hDBP locus: HSI and HSIII
at  2.1 kb and  0.13 kb upstream of the transcription
initiation site, HSIV and HSV within intron 1 and
HSVII located 30 to the poly(A) site. A second trans-
gene with minimal flanking sequences confirmed the
sufficiency of these gene-proximal determinants for
hepatic activation. The hepatic-specific HS aligned
with segments of phylogenetically conserved non-
coding sequences. These data demonstrate the
autonomy of the hDBP locus and suggest that this
controlismediatedbychromatin-basedlocuscontrol
determinants in close proximity to, and within the
transcription unit.
INTRODUCTION
The vitamin D-binding protein (DBP) gene is robustly
expressed in the livers of all mammalian species. In humans
the hDBP protein(alsoknownas Gc-globulin)issecretedfrom
hepatocytes asa polymorphic glycoprotein that constitutesone
of the most abundant serum proteins (232–464 mg/ml) (1). The
major function of serum DBP is the binding and transport of
25-hydroxyvitamin D, the major circulating form of vitamin D
and 1,25-dihydroxyvitamin D, the most active vitamin D
metabolite. DBP also binds tightly to monomeric G-actin,
blocking the formation of F-actin networks that may occlude
the vasculature following cellular damage. Several studies
suggest that covalent derivatives of DBP have pivotal roles
in the innate immune response by serving as a
macrophage-activating factor and by enhancing C5a-mediated
chemotaxis for macrophages and neutrophils [reviewed in ref.
(1–3)]. DBP is predominantly produced in hepatocytes,
although secondary minor sites of synthesis, such as the kid-
ney, have been identiﬁed (4). Due to its high-level of activity
anditswidespectrum offunctions,theDBPgene representsan
important model for the analysis of hepatic gene expression.
DBP is a member of a family of four robustly expressed
liver-speciﬁc genes. The conserved intron/exon organizations
along with primary and secondary structural conservation of
encoded proteins indicate a paralogous relationship of DBP to
albumin (ALB), a-fetoprotein (AFP) and a-albumin/afamin
(AFM). These four genes, formed by local duplications of a
common progenitor gene, remain physically linked in the
human and rodent genomes (2,5–10). Structural comparisons
among these genes suggest that DBP was the oldest and most
divergent member in this family (11–13). The developmental
proﬁles of these genes have been described. During rodent
embryonic development, expression of ALB, AFP and DBP
is induced in yolk sac and is maintained in fetal liver (14),
whereas the hepatic expression of AFM is initiated in the
perinatal period. AFP is selectively silenced at the end of
the fetal period, whereas ALB, AFM and DBP maintain
high constitutive levels of expression in adult liver (9). The
molecular mechanisms for the transcriptional activation of
these genes in the native hepatic chromatin environment,
and for their respective developmental controls, have yet to
be determined.
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DBP-ALB cluster, and the fact that they are all expressed
predominantly in liver, suggests that they may share one or
more common cis-regulatory determinants. The possibility of
shared regulatory control among these genes is supported by
the identiﬁcation of intergenic enhancers located between
ALB and AFP that have the potential to regulate both gene
promoters (15–18). Whether shared transcriptional control
elements are more widely involved in this four-gene family
has not been explored.
Models of regulatory elements controlling multi-gene fami-
lies can be found in the locus control regions (LCRs) for the
human and mouse b-globin gene clusters (19,20) and the
human growth hormone gene cluster (21). In these cases,
sets of regulatory elements, located quite distant from target
promoters, appear to act in concert to generate ‘open’ chro-
matin structures or chromatin ‘hubs’ (22) conducive to local
promoter access and transcription initiation. In some cases, the
genomic regions harboring regulatory elements can be located
as much as 1 Mb from the target promoter (23). Such remote
determinants can be located 50 or 30 of the target gene and in
some cases can reside within the introns of unrelated neigh-
boring gene(s) [reviewed ref. (24)]. The mechanistic basis for
such long-range control is presently under study. Whether the
DBP-ALB gene family is controlled by a common set of chro-
matin regulatory elements remains unknown. With the recent
clariﬁcation of the genomic organization of the DBP-ALB
multi-gene cluster, these questions can now be directly
addressed.
A recently reﬁned physical and meiotic map of the
4q11–q13 region in the human genome reveals the organiza-
tion of the cluster: centromere-30-DBP-50-50-ALB-30-50-AFP-
30-50-AFM-30-telomere (Figure 1A). Of particular note is the
inverse transcriptional orientation and wide (>1.5 Mb) separa-
tion of the DBP gene from the other three more tightly clus-
tered genes in the family (25) (GenBanK accession no.
NT_006216). The rat DBP (rDBP) multi-gene cluster is
located at 14p21–p22 in chromosome14, a region syntenic
to human chromosome 4, and the order and transcriptional
orientation of each gene correspond to the human cluster.
The distance betweenthe rDBP gene and the remaining family
members is also quite large (1.0 Mb) in rat (GenBank acces-
sion no. NW_047424). These data demonstrate that the organ-
ization, transcriptional orientation and expression patterns of
the DBP multi-gene clusters in rat and human are highly
conserved. Whereas the close juxtaposition of ALB, AFP
and AFM is consistent with the presence of common transcrip-
tionaldeterminants,thesubstantialseparationofDBPfromthe
other members suggests an alternative model of autonomous
control.
In the present report we test for autonomy of the DBP locus
using two sets of transgenic mouse models. We further begin
to explore its mechanistic basis by probing hepatic chromatin
by DNase I mapping for sites of potential transfactor interac-
tions. These studies indicate that determinants sufﬁcient for
establishment of an autonomous hepatic chromatin environ-
ment that supports robust hDBP expression in vivo are located
in close proximity to, and within, the hDBP gene itself. In our
transgenic setting, these locus control determinants are res-
ponsible for copy number dependent, site-of-integration
independent, and robust tissue-speciﬁc expression of the
hDBP locus. These data allow us to propose a model in
which the hDBP gene is independently regulated by a
dedicated LCR. It further implies that the DBP-ALB gene
cluster has evolved into at least two separable chromatin
units that maintain common liver speciﬁcity.
MATERIALS AND METHODS
Materials
Restriction and modiﬁcation enzymes were purchased from
New England Biolabs (Beverly, MA), Life Technologies
(Rockville, MD), and Roche Molecular Biochemicals
(Indianapolis, IN). [a-
32P]dCTP and MicroSpin G-50
Columns were purchased from Amersham Biosciences
(Piscataway, NJ). Random-primed DNA labeling kits and
Taq DNA polymerase were from Roche Molecular Bio-
chemicals. QIAEX II Kit was from QIAGEN and the GENE-
CLEAN II Kit was from BIO 101, Inc (La Jolla, CA). Elutip
columns were from Schleicher and Schuell (Keene, NH), and
RNAzol B RNA isolation solvent was from TEL-TEST Inc.
(Friendswood, TX). Zetabind membranes were from CUNO
Inc. (Meriden, CT).
Oligonucleotides
The various oligonucleotides listed in Table 1, were synthe-
sized by Life Technologies, Inc. or by the DNA Sequencing
Facility of University of Pennsylvania.
Preparation of DNA probes
The DNA probes for genomic Southern blots and northern
blots were released as EcoRI fragments from the rat (6) and
human (26) DBP cDNA plasmids. The MX probe, which
detects the unique sequence 30-ﬂanking region of the
mz-globin gene, was released as a 1.3 kb BamHI fragment
from the pMX plasmid (27). The mouse ribosomal protein L32
(mrpL32) cDNA probe was released as 0.32 kb EcoRI and
HindIII fragment from the mrpL32 plasmid (28). The probes
used for DNase I mapping were generated by PCR using Taq
DNA polymerase. The templates for the PCR were PAC
clones, 231M2 or 45P24 (25). Each fragment was recovered
using a QIAEX II kit from an agarose gel, and labeled by
[a-
32P] dCTP using a random-primed DNA labeling kit. Frag-
ments were then puriﬁed on MicroSpin G-50 columns.
Generation and analysis of transgenic mice
The 105kb-hDBP fragment was released from vector
sequences by NotI digestion of PAC clone, 231M2 plasmid
(25) and the 51kb-hDBP fragment by double-digestion of PAC
clone,45P24 plasmid (25) with NotI andFspI. Fragments were
separated by ﬁeld-inversion gel electrophoresis (FIGE) using
1% SeaKem LE agarose gels (FMC BioProducts, Rockland,
MA). Fragments were recovered with the GENECLEAN II
Kit or by electroelution. Each fragment was puriﬁed by
Elutip, diluted to 2 ng/ml in 10 mM Tris–HCl (pH 7.6),
0.1 mM EDTA and then microinjected into fertilized mouse
oocytes (University of Pennsylvania Transgenic and Chimeric
Mouse Core). Positive founders were detected by dot-blot
analysis of tail DNAs using hDBP cDNA 771 bp EcoRI
Nucleic Acids Research, 2006, Vol. 34, No. 8 2155fragment. The transgene copy number for each line was
determined by Southern blot analysis. All animal work
was carried out under protocols approved by the University
of Pennsylvania Institutional Animal Care and Usage
Committee.
Southern blot analysis
An aliquot of 10–15 mg of restriction enzyme-digested mouse
tail DNA was analyzed on 0.8% agarose gels, transferred to
Zetabind nylon membrane with 10· SSC (1.5 M NaCl, 0.15 M
sodium citrate), ultraviolet (UV) cross-linked to the mem-
brane. The membrane was prehybridized [0.5 M NaPO4
(pH 7.2), 7% SDS, 1% BSA and 200 mg/ml denatured salmon
sperm DNA] at 65 C, hybridized at 65 C with
32P-labeled
probe for 16 h, subsequently washed in 0.5· SSC, 0.1%
SDS at room temperature, and ﬁnally 0.1· SSC, 0.1% SDS
at 65 C. The washed membranes were exposed to XAR-5
ﬁlms (Kodak), and signals were quantiﬁed by phosphorimager
(Molecular Dynamics, Inc., Sunnyvale, CA).
Figure 1. Generation of transgenic mouse lines carrying the 105kb-hDBP transgene. (A) Isolation and characterization of the 105kb-hDBP transgene. The
arrangement of the human DBP, ALB, AFP and AFM genes and their transcriptional orientations (bent arrows) are shown at the top. Clones were isolated from
a human PAC library by PCR with a series of hDBP probes and the insert ends were sequenced using T7 and SP6 primers (25). PAC clone 231M2 encompasses a
105kbhumangenomicfragmentcontainingtheentire42kb-hDBPgenewithextended50-and30-flankingregions.Representativepartialdigestionpatternsof231M2
using four restriction enzymes indirectly end-labeled with a T7 probe are shown in the autoradiograph to the right. The deduced restriction map of 231M2 and the
positionofhDBPwithinthe231M2fragmentderivedfromthisanalysisaresummarizedattheleft.(B)Mappingandcopynumberdeterminationinfiveindependent
105kb-hDBPtransgeniclines.The 105kb-hDBP transgenewasreleasedfromPACclone231M2by digestionwithNotI (A),purified,andmicroinjectedto generate
transgenic founders. A series of five transgenic mouse lines were obtained. The transgene copy numbers were determined in the F1 generation of each line by
Southernblot analysis.Tail genomicDNA wasdigested withSacI andhybridizedwithan hDBPcDNA probe (303bp EcoRIfragment).GenomicDNA from HeLa
cells and the tail of a wild-type mouse were used as positive and negative controls, respectively. The lower diagram shows the 4.0 kb SacI fragment expected to
hybridize to the probe, as well as the location of this cDNA probe. The transgene-specific bands (4.0 kb, indicated by arrow) were quantified by phosphorimaging.
TransgenecopynumberswereestimatedbynormalizingthesesignalstothosefromhumangenomicDNA(HeLacell;twoendogenouscopies).Themousez-globin
was used as the DNA loading control. The deduced transgene copy numbers in the five lines ranged from 2 to 12 and are indicated below the corresponding lanes.
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Total RNA was extracted from various tissues with RNAzol.
5–20 mg of total RNA were denatured at 55 C, separated in
1.5% agarose-formaldehyde gels, and transferred to Zetabind
membrane with 10· SSC. After UV cross-linking, the blots
were prehybridized, and subsequently hybridized with
32P-labeled probes at 42 C for 16 h. The membranes were
washed with 2· SSC, 0.1% SDS at room temperature, and
ﬁnally 0.1· SSC, 0.1% SDS at 65 C. The washed membranes
were exposed to XAR-5 ﬁlms (Kodak), and signals were
quantiﬁed by phosphorimager (Molecular Dynamics, Inc.,
Sunnyvale, CA).
Radial immunodiffusion assay
One percent agarose containing 3% rabbit polyclonal
anti-hDBP (Cocalico Biologicals Inc., Reamstown, PA) was
poured on to a glass backing, and circular wells were cut into
the solidiﬁed matrix. Test mouse sera and the standard sera
containing hDBP protein (Calbiochem Inc., San Diego, CA)
(2–4 ml), were loaded into each well and allowed to diffuse for
40 h at room temperature. The gels were rinsed ﬁrst with
phosphate-buffered saline (PBS) for 16 h, then with distilled
water for 20 h. Gels were stained with 0.1% Coomassie
brilliant blue in 50% methanol and 10% acetic acid for
30 min, and subsequently de-stained with 50% methanol
and 10% acetic acid for 1 h. The amount of hDBP in each
serum sample was obtained by comparing the diameters of the
stained immunodiffused circles of each test serum and the
hDBP standard sera (50–500 mg/ml).
Isolation of intact nuclei
Livers of 105kb-hDBP transgenic mice were perfused with
cold PBS and minced. Liver nuclei were isolated as described
(29). The nuclei pellet was resuspended in buffer D [15 mM
Tris–HCl (pH 7.4), 15 mM NaCl, 60 mM KCl, 0.5 mM EGTA,
0.5 mM b-mercaptoethanol, 0.5 mM spermidine and 0.5 mM
spermine]. Brains of 105kb-hDBP transgenic mice were
washed in PBS. Brain cells were dissociated in cell-free
dissociation buffer (GIBCO-BRL, Grand Island, NY). Cells
were lysed in NB3 buffer [320 mM sucrose, 1 mM MgCl2,
0.05% Triton X-100, 1 mM Pipes (pH 6.4) and 0.1 mM
phenylmethylsulfonyl ﬂuoride (PMSF)]. Nuclei were washed
in RB buffer [0.1 M NaCl, 50 mM Tris–HCl (pH 8.0), 3 mM
MgCl2, 0.1 mM PMSF and 5 mM sodium butyrate], pelleted
and resuspended in RB buffer.
DNase I hypersensitivity mapping
The concentrations of nuclei were estimated from measure-
ments of A260/A280. 500 mg of liver nuclei were suspended in
buffer D with 5 mM MgCl2 and were incubated on ice for
10 min with increasing amounts of DNase I (GIBCO-BRL).
EDTA was added to 25–50 mM ﬁnal concentration to termi-
nate the reactions. The DNase I digested liver nuclei were
incubated in lysis buffer (800 mM NaCl, 0.5% SDS and
100 mg/ml proteinase K) at 55 C overnight. 100 mg of brain
nuclei were suspended in RB buffer with 1 mM CaCl2 and
incubated on ice for 10 min with increasing amounts of DNase
I (GIBCO-BRL). After terminating the reaction by adding
EDTA to 25–50 mM and an equal volume of lysis buffer
(1.6 M NaCl, 1% SDS and 200 mg/ml proteinase K),
DNase I digested brain nuclei were incubated at 55 C over-
night. The lysed liver or brain nuclei samples were extracted
with phenol and chloroform, and the DNAs were precipitated
with ethanol and suspended in TE buffer. The DNAs were
subsequently digested with appropriate restriction enzymes,
resolved by electrophoresis on 0.8–1.0% agarose gels, and
transferred to Zetabind nylon membranes for Southern blot
analysis.
RESULTS
Generation of mouse lines carrying the hDBP locus
with extensive flanking sequences (105kb-hDBP)
In order to assess the ability of the isolated hDBP gene to
establish an autonomous hepatic chromatin environment
capable of supporting consistent and robust expression, a
set of transgenic mouse lines were generated. To optimize
the possibility of including all necessary regulatory elements,
a large genomic fragment was used as transgene. The hDBP
gene encompasses 13 exons and spans 42 kb (13). Four human
genomic PAC clones containing the entire hDBP gene were
isolated from a PAC-recombinant library (25). Among them,
PAC clone 231M2 carried a 105 kb human genomic fragment
encompassing the entire hDBP gene along with 37 kb of
50-ﬂanking region and 26 kb of 30-ﬂanking region
(105kb-hDBP transgene; Figure 1A). This insert was released
from the PAC vector, microinjected into fertilized mouse
oocytes, and ﬁve founders were obtained. Each founder was
crossed with a CD1 mate to generate F1 transgenic mice and
ﬁve 105kb-hDBP lines were established. The integrity of the
transgene in each line was determined by extensive Southern
blot analysis of F1 or F2 tail DNA (Figure 1B and data not
shown). Transgene copy numbers ranged from 2 to 12 as
determined by Southern blot after the transgene signal was
normalized to the hDBP signal in total human (HeLa) DNA
(two copies) and to the endogenous mouse z-globin signal as a
loading control.
Expression of the 105kb-hDBP transgene
The expression of the 105kb-hDBP transgene was assessed to
determine whether the full complement of regulatory elements
Table 1. Oligonucleotide primers and probes
Probe Primer sequence
P1 50-TGGGGCACAATGGAATAGTTTG-30,
50-CCGAGATGCTGAAACAACCTAAGTG-30
P2 50-AGAAGACTGTCGCAGCATTAAAGG-30,
50-CAGATGGGGAAAAAATGGGTG-30
P3 50-CGCCTGAGTCTTTCAACCAATCTG-30,
50-CCCTGCATTTAATTTGGACGC-30
P4 50-CATCTGGGAAAGGAGGACTTCAC-30,
50-CTTAGGGCTTCCATCAAACCAATC-30
P5 50-ACTCCAACCTGGGTGACAGAGG-30,
50-GCTTTGCGAAACAATGAGGATG-30
P6 50-GCTTGAGAGTTTACCCAATTTCCA-30,
50-ACCTGATTATCAATGACTGAGATC-30
pI 50-GAATCACAGTAAGCAATCAA-30,
50-CTTTATCTCTGCTTTTGCAA-30
pIII 50-TCCCACTAAACAGATCTCAGTCAT-30,
50-GCAAGGACTTCATGTCTGAAACAG-30
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control was to determine whether these elements were able to
establish a chromatin environment that was autonomous and
independent of its site-of-insertion in the host genome. As
background for these studies, it has been previously demon-
strated that the endogenous rDBP locus is primarily expressed
in the liver with 100- to 1000-fold lower levels observed in
kidney, placenta/yolk sac, testis and abdominal fat and trace
levels in intestine and spleen (4). Northern blot analyses of the
105kb-hDBP transgene detected high levels of human DBP
mRNA in the liver of all lines, whereas signals of much lower
intensitywere consistentlyobservedinthekidney( 2–10%of
liver)(Figure 2A,upperpanelandsummarytable).Evenlower
levels were detected in the intestines of 3 of 5 lines
( 0.6–1.0% of liver), and sporadically in testes and spleen
(Figure 2A and data not shown). The expression proﬁle of the
endogenous mouse DBP gene (mDBP) was established in
parallel (Figure 2A, middle panel). Overall, the expression
proﬁle of the 105kb-hDBP transgene was consistent with
that of the endogenous mDBP gene. These data indicated
that the 105kb-hDBP transgene contains regulatory compo-
nents sufﬁcient to establish native patterns of expression and
that the mouse has all the regulatory factors necessary to
support the native expression pattern of the human DBP gene.
The ability of the 105kb-hDBP transgene to establish a fully
productive and autonomous chromatin domain was further
Figure 2. The 105kb-hDBP transgene programs full level, tissue-specific and copy number dependent expression. (A) Tissue specificity of 105kb-hDBP transgene
expression. The autoradiograph shows a Northern blot surveying a set of tissues from a representative 105kb-hDBP transgenic line (mouse line 6). RNAs from the
indicatedtissuesandcontrolRNAfromwild-typemouseliver(WT)wereanalyzed.TheNorthernblotwashybridizedwithanhDBPcDNAfragmentandthenwitha
mouseribosomalproteinL32(mrpL32)cDNAfragmenttonormalizeforRNAloading.ThehDBPcDNAprobewasspecificforthehumanDBPmRNAanddidnot
cross-hybridize to the mouse DBP mRNA. The blot was stripped then re-hybridized with rat DBP cDNA to detect the cross-hybridizing, endogenous mouse DBP
mRNA. The 105kb-hDBP transgene was expressed predominantly in the livers and at lower level in the kidney of each line. The table summarizes the tissue
distribution of transgene expression in an adult male mouse of each transgenic line (-; no signal detected). Expression in the liver is defined as 100 and all values in
othertissuesarecalculatedasusingthisasareference.Verylow-levelexpressionwasdetectedinintestinesofthreelinesandoccasionallyinspleenortestis.(B)Copy
number dependency of 105kb-hDBP transgene expression. Northern blots containing liver RNA from the five 105kb-hDBP transgenic lines were hybridized with
hDBPcDNAandthenmrpL32cDNA.ThreeanimalsfromeachlinewereanalyzedandarepresentativeNorthernblotisshown.hDBPmRNAwasquantifiedforeach
lineandnormalizedtothemrpL32signaltocorrectforRNAloading.ThecorrectedhDBPexpressionvaluewasdividedbytransgenecopynumberandthemeanratio
for line 1 was arbitrarily set to 1.0. The ratios from the remaining lines were normalized to line 1 and were plotted on the bar graph (±SD). All quantifications were
done by phosphoimager analysis andall were in the linear rangeofdetection(Materials and Methods).Therewere nostatisticallysignificantdifferencesamongthe
lines when hDBP expression was normalized to transgene copy number. A radial immunodiffusion assay was used to quantify levels of serum hDBP in each
transgenicline.TheserumhDBPlevelspertransgenecopynumberwereplottedinthebottompanelusingalogarithmicscale.Theresultsdemonstratedthattheliver
hDBP mRNA and serum hDBP levels were remarkably consistent from line to line in a copy number dependent fashion.
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expression levels and 105kb-hDBP transgene copy number
(Figure 2B). If the transgene contains locus control determi-
nants sufﬁcient to establish an autonomous chromatin domain,
expression of the transgene at each independent insertion site
should be directly related to transgene copy number. This was
tested in the case of the hDBP transgene at both the levels of
mRNA expression and protein production. hDBP mRNA
levels in the livers of mice from each of the ﬁve 105kb-
hDBP lines were quantiﬁed by northern analyses. Levels of
hDBP mRNA were normalized to endogenous mouse
ribosomal protein L32 (mrpL32) mRNA as a loading control
and divided by transgene copy numbers to generate an expres-
sion per transgene copy value (Figure 2B, autoradiograph). A
tight correlation was observed among values from the ﬁve
lines, lying within a 2-fold range. The correlation between
transgene copy number and levels of gene expression was
conﬁrmed by analyses of serum hDBP protein levels. The
serum hDBP levels/transgene copy number in adult mice
from the ﬁve lines fell within a 3-fold range, ranging from
85–233 mg/ml/copy. Remarkably, the levels of serum hDBP in
these 105kb-hDBP mouse lines, when corrected for transgene
copy number, approximated the range of normal human serum
DBP levels (116–232 mg/ml/copy) (1) (Figure 2B, graph).
There was no evidence for sexual dimorphism of transgene
expression (data not shown). These results demonstrated site-
of-integration independent, copy number dependent and
tissue-speciﬁc expression of the 105kb-hDBP transgene.
This was consistent with the establishment of an autonomous
chromatin domain by the transgene and furthermore was con-
sistent with the presence of determinants that constitute a LCR
(19,30,31).
Liver-specific DNase I hypersensitive sites (HS) are
established at the 105kb-hDBP chromatin locus
The transgene expression studies (Figures 1 and 2) indicated
that determinants sufﬁcient for establishment of a fully pro-
ductive hDBP locus in native hepatic chromatin are encom-
passed within the 105kb-hDBP transgene. To identify
candidate regions that contain the relevant LCR determinants,
DNase I mapping was performed on the 105kb-hDBP trans-
genic liver chromatin. Regulatory sequences involved in such
LCR function commonly localize to DNase I HS within the
chromatin of expressing tissues [reviewed in ref. (32,33)].
With this tissue speciﬁcity in mind, chromatin from the
brain (negative control) of 105kb-hDBP transgenic mice
was also mapped with DNase I. A mapping approach was
designed to cover the entire gene and its adjacent ﬂanking
regions. A representative analysis of the 26 kb BglI fragment
that spans the 50 terminus of the gene (from  17.4 to +8.6 kb)
isshown(Figure3A).Aprobehybridizing tothe30 terminus of
this fragment (probe P1) revealed two strong liver-speciﬁc
DNase I HS and one weak brain-speciﬁc HS in the promoter
region (Figure 3A). Higher resolution analyses of these
HS were obtained by probing a 6.7 kb HindIII fragment
spanning sequences  3.0 to +3.7 kb (probe P2)
(Figure 3B). This study conﬁrmed the presence of the two
liver-speciﬁc HS (HSI at  2.1 kb and HSIII at  0.13 kb)
as well as the two additional HS speciﬁc to the brain
(HSII-1 at  1.8 kb and HSII-2 at  1.5 kb).
DNase I mapping was extended throughout the hDBP gene
and its 30-ﬂanking region (Figure 4 and data not shown). These
analyses detected four additional HS in liver: HSIV, HSV,
HSVI and HSVII. HSIV and HSV are located within intron 1
(Figure 4A and B). The broader and stronger HSIV was com-
posed of at least three sub-signals, located at map coordinates
+10.3 kb to +10.9 kb. A weaker HSV was located at +12.2 kb.
Two additional HS were observed at the 30 terminus of the
gene; HSVI (+42.7 kb) coincident with the polyA site was
presentinbothliverandbrainandhence wasnotliver-speciﬁc.
In contrast HSVII (+43.9 kb), located immediately 30 to HSVI,
was liver-speciﬁc (Figure 4C). The full HS mapping strategy
and a summary of the results are shown (Figure 4D).
HSI is located  2.1 kb relative to the site of hDBP tran-
scriptional initiation. It is of note that the sequences corre-
sponding to HSI as well as HSIII are highly conserved.
Comparison of the sequences at HSI demonstrated over
80% identity between human and rodent [GenBank accession
no. L10641, L10642 (human), MW_047424 (rat) and
NT_039308 (mouse)], (Figure 5, upper). Such conservation
of non-coding sequences in genomic alignments is a reliable
indicator ofregulatorydeterminants (34–36).Theproximityof
HSIwithHSIIIsuggestedthatthetwomightworkinconcertto
coordinate hDBP promoterfunction. Genomic sequence align-
ments also revealed a remarkable conservation of non-coding
sequences within intron 1. This conserved segment is coinci-
dent with the 1.9 kb region bracketed by HSIV and HSV
(Figure 5, lower). Sequence comparisons of the human and
rodent DBP loci demonstrated that HSVI and HSVII in the 30
terminus region also correspond to segments with over 70%
sequence similarity (data not shown). Thus, a set of liver-
speciﬁc HS was identiﬁed at the 105kb-hDBP transgene
locus in hepatic chromatin and these sites are coincident
with segments of conserved non-coding sequences in the
50-ﬂanking region, in intron 1, and in the 30-ﬂanking region.
This concordance of HS mapping and localized segments of
phylogenetically conserved non-coding sequences supports
functional roles for these regions in hDBP expression.
Generation of 51kb-hDBP transgenic mouse lines
Determinants involved in chromatin organization and LCR
activity are characteristically located quite distant from a tar-
get gene. The HS identiﬁed in the preceding studies (Figures 3
and 4) are in close proximity to, or within, the hDBP tran-
scription unit. To test whether these gene-proximal HS are
sufﬁcient for hDBP activation, a second set of mouse lines
was generated using a transgene with minimal ﬂanking
sequences. This 51 kb genomic fragment, excised with NotI
and FspI from the 123 kb human genomic PAC clone (PAC
45P24), encompassed the entire hDBP gene along with only
2.5 kb of 50-ﬂanking and 6.5 kb of 30-ﬂanking region (51kb-
hDBP transgene; Figure 6A and B). Four transgenic founders
were generated. Transgene integrity and copy numbers were
determined for each line (Figure 6C).
Liver-specificandcopynumberdependentexpressionof
the 51kb-hDBP transgene
High-level hDBP mRNA expression was detected in the livers
of all four 51kb-hDBP transgenic lines (Figure 7A autoradio-
graph and data not shown). hDBP mRNA was also detected by
Nucleic Acids Research, 2006, Vol. 34, No. 8 2159northern blot analysis at trace levels in the kidneys of two
of the four 51kb-hDBP lines (0.05 and 0.04% of expression
levels in livers, respectively); in the remaining two 51kb-
hDBP lines expression in the kidney could not be detected
(Figure 7A table and data not shown). Serum hDBP levels
in the four 51kb-hDBP lines varied by less than 3-fold
(80–189 mg/ml/transgene copy), indicating copy number
dependent expression (Figure 7B). These levels were remark-
ably similar to those observed in the sera of 105kb-hDBP
transgenic mice and similarly approximate the levels of
expression of the native hDBP gene (1) (Figure 2B). These
data demonstrated that the 51kb-hDBP transgene, containing
only 2.5 kb of 50-ﬂanking region and 6.5 kb of 30-ﬂanking
region, was able to overcome site-of-integration position
effects and direct high levels of liver-speciﬁc hDBP gene
expression from multiple random integration sites in trans-
genic mouse chromatin. In addition, we note a selective
loss of hDBP transgene expression in the kidneys of the
51kb-hDBP mice when compared with the 105kb-hDBP trans-
gene, suggesting that expression in the kidney may rely on a
distinct set of determinants.
DISCUSSION
In the present report we have tested for autonomous regulation
of the hDBP gene and have sought sites in the native hepatic
chromatin that might encompass relevant regulatory elements.
Many transgenes are not consistently or accurately expressed
in the mouse due to the exclusion of determinants that are
necessary to re-establish the native chromatin environment.
Thus these transgenes are sensitive to the major inﬂuences,
both positive and negative, at the foreign site-of-integration in
the host (mouse) genome. An LCR is deﬁned by its ability to
re-establish a chromatin environment that is dominant over
site-of-integration effects. Thus the LCR action allows the
transgene to be expressed at a consistent level when compared
among multiple lines, each representing a unique insertion
site. The initial approach in our study was to introduce the
hDBP gene with extensive ﬂanking sequences into the mouse
genome and determine whether it could establish an appropri-
ate pattern and level of gene expression. The results clearly
demonstrated that this was the case. The pattern of expression
of the hDBP transgene encompassing 37 kb of 50-ﬂanking
Figure 3. Twoliver-specificDNaseIHSarepresent50 tothehDBPgene.(A)Mappingthe50-flankingDNaseIHSusingadownstreamprobe.ABglI(B)restriction
map of the hDBP gene and flanking regions from position  37 to +68 kb is shown at the top. The position of hybridization probe P1 is labeled and the 26 kb BglI
fragment subjected to mapping is indicated (horizontal double-headed arrow). DNase I HS mapping was carried out on chromatin isolated from 105kb-hDBP liver
andbrain(negativecontrol),leftandrightautoradiographs,respectively.AliquotsofchromatinweresubjectedtoincreasingamountsofDNaseI(wedges).Genomic
DNAfromthesealiquotsweredigestedtocompletionwithBglIandsubjectedtoSouthernanalysis.The26kbBglIfragmentspanningthe50-flankingregion,exon1
andpartofintron1wasmappedbyhybridizationtoprobeP1(seeTable1).Twoprominentliver-specificDNaseIHS(HSIandHSIII)wereidentifiednearthehDBP-
proximalpromoterregion.AsingleweakHS(HSII)wasidentifiedonlyinthecontrolbrainsample.Theresultsaresummarizedonthemapundertheautoradiographs.
VerticalarrowsindicatethepositionsoftheDNaseIHS(#;liver,";brain).Thehorizontalarrowsbelowthemapindicatefragmentsizes(kb)andtheirdesignations.
(B)Refinedmappingofthe50-flankingDNaseIHSusinganupstreamprobe.TheDNaseImappingresultsin(A)wereconfirmedusingaprobelocatedupstreamof
thesitesandatahigherlevelofresolution.Themapatthetopshowsthe6.7kbHindIII(H)fragmentthatencompassestheidentifiedDNaseIsitesandthelocationof
probe P2 (Table 1). The Southern analysis of liver chromatin samples as in (A) confirmed the presence of the two liver-specific DNase I HS (HSI and HSIII). In the
analysis of this shorterfragment,the brain-specific sitewas resolved into two closelylinked HS (designatedHSII-1and HSII-2).The results ofthe refinedmapping
are summarized on the map under the autoradiograph, as in (A).
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Figure 4. Two sets of HS are formed within intron 1 and 30 of hDBP gene. (A) Mapping strategy. The BglI (B) and FspI (F) restriction map of the 105kb-hDBP
transgene (positions  37 through +68 kb) indicates the locations of the probes (P3 and P6) used to map HS throughout the gene and into the 30-flanking region.
(B) Mapping the HS in intron 1. A 6 kb BglI fragment of intron 1 was mapped using probe P3 that is itself located in intron 1. Two HS were identified in liver
chromatin, the more intense and broad HSIV at position +10.3 to +10.9 kb and HSV at position +12.2 kb (positions are relative to the transcription initiation site).
These sites are placed on the map below the autoradiograph. Exon 2 (E2) is shown in this map as a filled rectangle. (C) Mappingthe hDBP gene 30-flanking region.
ProbeP6wasusedtomapa9.0kbBglI–FspIfragmentspanningterminalexon13andthe30-flankingregionofhDBPgene.Themapbelowtheautoradiographshows
thelocationofprobeP6usedtomapHSwithinthe30 flankingregion.HSVI,commontobothliverandbrain,andliver-specificHSVIIweredetected.Theirpositions
are placed on the map below the autoradiograph. (D) Summary of DNase I mapping the 105kb-hDBP transgene. The results of the DNase I mapping of the entire
105kb-hDBP transgene (Figures 3 and 4 and data not shown) are summarized. The positions of probes used in the mapping and the specific restriction fragments
mappedareindicatedonthetopdiagram(P1–P6;probes,B;BglI,F;FspI,H;HindIII).ThepositionsofeachHSareshowninthelowermapthatalsoshowspositions
of the 13 exons (numbered black rectangles) and 12 introns of hDBP gene. Vertical arrows indicate the DNase I HS identified (#; liver, "; brain).
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transgene) paralleled that of the endogenous DBP locus. This
result represents the analysis of ﬁve independent lines. Not
only was the robust expression primarily restricted to the liver,
but the major secondary site of DBP expression in the kidney
was also preserved (Figure 2A). Of particular note, the level
of transgene expression, when monitored at the protein level
and normalized to transgene copy number, was remarkably
Figure 5. Comparisons between human and rodent genomic sequences in the vicinity of the DBP locus. A map of the hDBP gene is displayed in the center of the
figure showing the exon-intron arrangement and location of the HS in liver (downward arrows) and brain (upward arrows). An expanded view of the sequence
comparisons (human compared to rodent) in the 50-flanking region (upper panel) and intron 1 (lower panel) are shown. The numbering on the x-axis refers to the
position in the human sequence. The level of similarity in sequence is displayed on the y-axis as a percentage (mVISTA program; window size 50 bp, homology
threshold70%).The75%levelofsequencesimilarityismarkedbyahorizontallineandregionsofthesequencerepresentingrepeatedelementsareindicatedbythe
shaded rectangles,LINE elements (stippled)and SINE (solid). The positionsof liver-specific HSI, HSIII, HSIV and HSV sequence comparisons are each indicated
by the downward arrows. Note the peaks of sequence identity at each of the indicated DNase I HS.
Figure6.Generationoftransgenicmouselinesusingthe51kb-hDBPtransgene.(A)Mapofthe51kb-hDBPtransgene.PACclone45P24(25)wasdigestedwithNotI
andFspItogeneratethe51kb-hDBPtransgene.This51kbtransgeneencompassesthehDBPgenewith2.5kbof50-flankingand6.5kb30-flankingregions,including
all ofthe liver-specific DNaseI HS detected.Positionsofprobes used to confirmthe structureofthe transgene are indicated(pI,pII, derivedfrom the hDBP cDNA,
andpIII;Table1)(B)SouthernblotanalysisofPACclone45P24confirmedthestructureofthe51kbfragment.InsertDNAwasreleasedwithNotIdigestionfromthe
PACvectorandthe51kbfragmentwasobtainedwithNotIandFspIdouble-digestions.SouthernblotsofthesedigestionswereprobedwithradiolabeledpI,pIIorpIII
(A). Asingle51kbbandwasdetectedwitheach probeasexpected.(C) Analysisof51kb-hDBPtransgeniclinesandcopynumberdeterminations.Four51kb-hDBP
mouselinesweregenerated(910D,924B,955Band955E).ThetransgenecopynumbersweredeterminedinF1orF2generationsofeachlinebySacIdigestionand
Southern blot analysis as described (Figure 1B). The copy numbers determined (ranging from 6 to 22) are indicated below the corresponding lines.
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(Figure 2B). Thus, the 105kb-hDBP transgene was expressed
in a site-of-insertion independent and copy number dependent
manner, at full levels, and with appropriate tissue speciﬁcity.
From these data we concluded that the determinants sufﬁcient
to establish an autonomous and fully active chromatin locus
capable of supporting full and accurate hDBP expression are
within and/or closely linked to the hDBP gene. These deter-
minants fulﬁll the operational deﬁnition of an LCR.
The second phase of the study was to map the determinants
involved in the activation of the hDBP gene in hepatic chro-
matin. LCR determinants commonly map to sites of DNase I
hypersensitivity (HS) in the chromatin of expressing cells.
These HS reﬂect the localized displacement of histones or
perturbation in chromatin structure by trans-acting factors
binding at the site (37,38). Core elements that have been
deﬁned at individual HS are usually composed of arrays of
multiple tissue-speciﬁc and ubiquitous transcription factor-
binding sites [reviewed in ref. (32,33)]. With this in mind,
the 105kb-hDBP transgene locus was mapped for HS in hep-
atic tissue as well as in brain, a non-expressing tissue. A set of
ﬁve liver-speciﬁc HS was identiﬁed (Figure 4D). HSI and
HSIII are located at  2.1 and  0.13 kb relative to the
hDBP promoter, respectively, whereas HSIV and HSV are
closely juxtaposed within a 1.9 kb region of intron 1
(10.3–10.9 kb and 12.2 kb, respectively). HSVII maps to a
site 1.5 kb 30 to the poly(A) addition site. HSVI, although
detected in liver, was also present in brain chromatin and
thus not tissue-speciﬁc. To support the sufﬁciency of these
elements to activate of hDBP, we assessed the expression of a
second transgene with minimal ﬂanking sequences just long
enough to encompass the full set of identiﬁed HS. High-level,
copy number dependent and liver-speciﬁc expression of this
shorter 51kb-hDBP transgene was observed in all four 51kb-
hDBP transgenic lines. These results suggested that all deter-
minants necessary for the establishment of a fully functional
chromatin locus are present within the 51kb-hDBP transgene.
These data support a model in which the set of determinants
identiﬁed by the HS mapping constitute a liver-speciﬁc hDBP
LCR and are sufﬁcient for hDBP activation in the transgenic
setting.
The exact structure and mode of action of the determinants
at each of the HS remains to be established. Our prior assays in
cell transfection systems had identiﬁed three functional
HNF1-binding sites within the proximal 2 kb of the rat
DBP gene (rDBP)5 0-ﬂanking region (39). The region from
 65 to  41 bp, the ‘A segment’, is the most proximal
HNF1-binding site. Two more distal HNF1-binding sites,
located in segments ‘B’ and ‘F-2’ (coordinates at  254 to
 140 bp and  1844 to  1621 kb, respectively), function
as classical enhancer elements. The B and F-2 segments
both increase the activity of homologous and heterologous
promoters when assayed in transfected HepG2 liver-derived
cells. HNF1-a played a predominant role in the observed
enhancer function. At the B and F-2 sites the HNF1b protein
showed a trans-dominant negative effect on HNF1a-
stimulated activity of the rDBP promoter suggesting that
the relative levels of HNF1a and HNF1b in various tissues
might contribute, in part, to tissue-speciﬁc expression of DBP
in vivo (39). HSIII, detected in the present study, is located
between the two HNF1-binding sites corresponding to the A
and B binding sites described in the rDBP proximal promoter.
This suggests that the formation of HSIII reﬂects local
promoter complex assembly. HSIII is co-located to a highly
conserved region among human, mouse and rat (Figure 5). The
Figure 7. 51kb-hDBP transgene expression is liver-specific and copy number
dependent. (A) Tissue specificity of 51kb-hDBP transgene expression. A
Northernblottissuesurveyfromarepresentative51kb-hDBPtransgenicmouse
line (line 924B, transgene copy number 6) is shown. The probes used are
indicatedontheleftoftheautoradiograph.High-levelliver-specificexpression
of the 51kb-hDBP transgene was observed. The table summarizes the relative
quantificationoftransgeneexpressioninvarioustissuesofanadultmalemouse
from each of the four 51kb-hDBP lines; the expression of hDBP mRNA in the
liver is defined as 100 in each line and expression in other tissues is related to
this value. (B) Copy number dependency of 51kb-hDBP expression. Serum
hDBPlevelper transgenecopy ofeach 51kb-hDBP linewasquantified.Means
and SD were calculated from serum hDBP levels of at least eight mice in each
line.ConsistentandcopynumberdependentserumhDBPlevelswereobserved.
Theselevelswere concordantwith thelevelsin the 105kb-hDBPlinescarrying
the more extensive hDBP gene flanking regions.
Nucleic Acids Research, 2006, Vol. 34, No. 8 2163detection of HSIII in this region supports the previous
conclusion that the two HNF1-binding sites in the proximal
promoter are critical elements for hDBP activation.
A comparison of the current studies with previous analyses
of ALB and AFP genes highlights points of potential interest.
Consistent with other numerous model systems, transgenic
studies at the mouse ALB locus have revealed that the pro-
moter region is insufﬁcient for robust and consistent transgene
expression. These studies identiﬁed a transcriptional enhancer
located 10 kb upstream of the transcription start site that is
essential for full liver-speciﬁc expression (40). This element
co-maps with a strong liver-speciﬁc HS (40,41) and in vitro
studies have demonstrated that this enhancer can trigger the
activation of a compacted chromatin template (42). Analysis
of the mouse AFP gene has identiﬁed three enhancer elements
at  2.5,  5.0 and  6.5 kb relative to the promoter (43,44). All
three sites were required to achieve high-level expression of
ALB in fetal liver (45). In contrast to these ﬁndings for the ALB
and AFP genes, the current report reveals that the hDBP trans-
gene is robustly activated in vivo in the absence of remote
ﬂanking determinants. These data along with the HS mapping
raise the possibility that HSIV, possibly in concert with the
substantially weaker HSV, mediates enhancer functions com-
parable to the distal enhancers far upstream of ALB or AFP
promoter. In light of other studies in the literature, the intronic
location of HSIV and HSV is fully compatible with their
functioning as dominant locus control element(s) (46–51).
The broad and multipartite structure of HSIV is consistent
with multiple arrays of transcription factor-binding sites, a
composition common among LCR elements (32,33).
In addition to its expression in the liver, human and rodent
DBPs are also expressed at substantially lower levels in
several secondary sites. The most prominent and well
described of these is in the kidney. The local expression of
DBP in the kidney may be important in vitamin D recycling
via interactions with the renal scavenger protein megalin
(52–54). While the transcriptional initiation site for hDBP
in the two tissues appears to be identical (4), it is likely
that the complex of determinants driving expression in this
secondary site differ from those in the liver. The 105kb-hDBP
transgene paralleled the endogenous mDBP with respect to
kidney expression; hDBP expression was observed at consid-
erable levels ( 2–10% of liver) in the kidneys of all ﬁve
105kb-hDBP lines. In contrast, kidney expression of the
more truncated 51kb-hDBP transgene was sporadic while
liver expression remained robust and consistent. We have
generated a single transgenic mouse line carrying a 123 kb
insert of PAC clone 45P24 (Figure 6A). This transgene has the
same 50 terminus as the 51kb-hDBP at  2.5 kb as well as a
more extensive 78 kb 30-ﬂanking region. The tissue distribu-
tion of hDBP expression from this transgene by Northern blots
showed robust liver expression and an absence of expression
in the kidney (data not shown). These results suggest that one
or more important elements for kidney hDBP expression are
located in the region between +37 kb and +2.5 kb upstream
from the transcription start site. Whether these elements will
constituteakidney-speciﬁcelementofthe hDBP LCRremains
to be determined.
In conclusion, the present study demonstrates that elements
critical to hepatic activation of the hDBP gene and establish-
ment of a fully autonomous chromatin domain are located in
close proximity to, and within the hDBP gene. The combina-
tion of transgenic studies, HS mapping and phylogenetic
sequence comparisons establish a model in which HSI,
HSIII, HSIV, HSV and HSVII constitute components of a
liver-speciﬁc LCR. How each element contributes to this
activity can now be further explored. These data further estab-
lish a functional independence of hDBP from the other mem-
bers of its cluster. This suggests that critical elements that
trigger the hepatic expression of these genes have duplicated
during evolution and are represented at multiple sites within
the cluster. It remains possible, that at some higher level of
nuclear organization, these elements may interact to facilitate
and coordinate their respective developmental proﬁles.
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